Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge

Journal of Clinical Virology

Volumn 78, Issue , 2016, Pages 27-30

  De Monte, Anne ^a   Courjon, Johan ^a   Anty, Rodolphe ^a,b,c   Cua, Eric ^a   Naqvi, Alissa ^a   Mondain, Véronique ^a   Cottalorda, Jacqueline ^a   Ollier, Laurence ^a   Giordanengo, Valérie ^a,c,d  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b INSERM   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

HBV reactivation; HCV Direct Acting Antivirals; HIV infection; NS3 4A protease inhibitors; NS5A inhibitors; NS5B polymerase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B(E) ANTIGEN; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; TENOFOVIR; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG WITHDRAWAL; ELASTOGRAPH; ELASTOGRAPHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIMIT OF DETECTION; MALE; MEDICAL HISTORY; MIDDLE AGED; MIXED INFECTION; OSTEOPOROSIS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIRUS LOAD; VIRUS REACTIVATION; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; DRUG EFFECT; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; VIRUS ACTIVATION;

EID: 84960129961     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.02.026     Document Type: Article

References (24)

1. Webster D.P., Klenerman P., Dusheiko G.M. Hepatitis C. Lancet Lond. Engl. 2015, 385:1124-1135.
2. European Association for Study of Liver EASL recommendations on treatment of hepatitis C. J. Hepatol. 2015, 63:199-236.
3. AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015, 62:932-954.
4. Collins J.M., Raphael K.L., Terry C., Cartwright E.J., Pillai A., Anania F.A., et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin. Infect. Dis. 2015, 10.1093/cid/civ474.
5. Ende A.R., Kim N.H., Yeh M.M., Harper J., Landis C.S. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J. Med. Case Reports 2015, 9:164.
6. Takayama H., Sato T., Ikeda F., Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with HBV/HCV co-infection. Hepatol. Res. 2015, 10.1111/hepr.12578.
7. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49:S156-S165.
8. Jindal A., Kumar M., Sarin S.K. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int. 2013, 33:164-175.
9. Konstantinou D., Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol. 2015, 28:221-228.
10. Dai C.Y., Yu M.L., Chuang W.L., Lin Z.Y., Chen S.C., Hsieh M.Y., et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2001, 16:636-640.
11. Fong T.L., Di Bisceglie A.M., Waggoner J.G., Banks S.M., Hoofnagle J.H. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991, 14:64-67.
12. Sagnelli E., Coppola N., Marrocco C., Onofrio M., Sagnelli C., Coviello G., et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J. Clin. Virol. 2006, 35:317-320.
13. Coffin C.S., Mulrooney-Cousins P.M., Lee S.S., Michalak T.I., Swain M.G. Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int. 2007, 27:722-726.
14. Potthoff A., Berg T., Wedemeyer H. HEP-NET B/C Coinfection Study Group: late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand. J. Gastroenterol. 2009, 44:1487-1490.
15. Chen S.-Y., Kao C.-F., Chen C.-M., Shih C.-M., Hsu M.-J., Chao C.-H., et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J. Biol. Chem. 2003, 278:591-607.
16. Schüttler C.G., Fiedler N., Schmidt K., Repp R., Gerlich W.H., Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J. Hepatol. 2002, 37:855-862.
17. Pasquinelli C., Shoenberger J.M., Chung J., Chang K.M., Guidotti L.G., Selby M., et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997, 25:719-727.
18. Pan Y., Wei W., Kang L., Wang Z., Fang J., Zhu Y., et al. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochem. Biophys. Res. Commun. 2007, 359:70-75.
19. Eyre N.S., Phillips R.J., Bowden S., Yip E., Dewar B., Locarnini S.A., et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J. Hepatol. 2009, 51:446-457.
20. Bellecave P., Gouttenoire J., Gajer M., Brass V., Koutsoudakis G., Blum H.E., et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009, 50:46-55.
21. Wiegand S.B., Jaroszewicz J., Potthoff A., Höner zu Siederdissen C., Maasoumy B., Deterding K., et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin. Microbiol. Infect. 2015, 21:710.e1-710.e9.
22. Guo H., Zhou T., Jiang D., Cuconati A., Xiao G.-H., Block T.M., et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J. Virol. 2007, 81:10072-10080.
23. Dumoulin F.L., von dem Bussche A., Li J., Khamzina L., Wands J.R., Sauerbruch T., et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology 2003, 305:260-266.
24. Song K., Han C., Dash S., Balart L.A., Wu T. MiR-122 in hepatitis B virus and hepatitis C virus dual infection. World J. Hepatol. 2015, 7:498-506.